When was HilleVax founded?

HilleVax was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is HilleVax located?

HilleVax is headquartered in Boston, United States.

Who is the current CEO of HilleVax?

Aditya Kohli of HilleVax. They are also an angel investors in 1 startup.

How many employees does HilleVax have?

As of Dec 31, 2022, the latest employee count at HilleVax is 62.

Is HilleVax a funded company?

HilleVax is a funded company, having raised a total of $***** in its 1st and only funding round, a Series D round on Sep 08, 2021.

When was the latest funding round of HilleVax?

HilleVax's latest funding was a $***** Series D round on Sep 08, 2021, with participation from 13 investors.

Where does HilleVax rank among its competitors?

HilleVax ranks 5th amongst 46 active competitors, of which 11 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was MAXVAX Biotechnology, which secured an undisclosed amount in Dec, 2025.

Who are the top competitors of HilleVax?

HilleVax's top competitors include Dynavax, Sinovac and VBI Vaccines. Among them, MAXVAX Biotechnology secured the most recent funding round in December, 2025.

HilleVax - 2026 Company Profile, Team, Funding, Competitors & Financials

HilleVax is a public company based in Boston (United States), founded in 2021 by Aditya Kohli. It operates as a Developer of a vaccine for norovirus infection. HilleVax has raised $135M in funding from Frazier Healthcare Partners. The company has 46 active competitors, including 11 funded and 13 that have exited. Its top competitors include companies like Dynavax, Sinovac and VBI Vaccines.

Company Details

Developer of a vaccine for norovirus infection. The lead candidate HIL-214 is a norovirus bivalent GI.1/GII.4 virus-like particle vaccine indicated for active immunization for the prevention of acute gastroenteritis caused by norovirus.

Website: hillevax.com
Social
Email ID: *****@hillevax.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Boston, United States

Stage

Public

Total Funding

$135M in 1 round

Latest Funding Round

Series D, Sep 08, 2021, $*****

Investors

Frazier Healthcare Partners & 12 more

Ranked

5^th among 46 active competitors

Employee Count

62 as on Dec 31, 2022

Similar Companies

Dynavax & 53 more

Exit Details

Public

View HilleVax's full profile

HilleVax is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HILLEVAX, INC. CIN: 1888012 , United States, Active	Mar 24, 2020	-	-	-
HILLEVAX, INC CIN: 85-0545060 , United States, Active	Mar 24, 2020	-	62 (As on Dec 31, 2022)	-

HilleVax got listed on Apr 29, 2022.

Click here to take a look at HilleVax's IPO in detail

HilleVax has raised a total funding of $135M over 1 round. Its latest funding round was a Series D round on Sep 08, 2021 for $*****. 13 investors participated in its latest round. HilleVax has 13 institutional investors.

Here is the list of recent funding rounds of HilleVax:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 08, 2021	4860173	Series D	1891762	8624461	9591939	4106214

Access funding benchmarks and valuations. Sign up today!

View details of HilleVax's funding rounds and investors

The founders of HilleVax is Aditya Kohli.

Here are the details of HilleVax's key team members:

Aditya Kohli: Co-Founder, CEO and Chairman of the Board of HilleVax. They are also an angel investor in 1 startup.
Contact Info: 2 email addresses

View details of HilleVax's Founder profiles and Board Members

HilleVax's employee count trend

HilleVax has 62 employees as of Dec 22. Here is HilleVax's employee count trend over the years:

Uncover HilleVax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HilleVax include Dynavax, Sinovac and VBI Vaccines. Here is the list of Top 10 competitors of HilleVax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Dynavax 1996, Berkeley (United States), Acquired	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Care Capital, Axiom Venture Partners & 27 others	70/100
2nd	Sinovac 2001, Haidian (China), Acquired	Developer of vaccines against multiple infectious diseases	-	Vivo Capital, Sino Biopharmaceutical & 3 others	64/100
3rd	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	60/100
4th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	59/100
5th	HilleVax 2021, Boston (United States), Public	Developer of a vaccine for norovirus infection	$135M	RA Capital Management, Perceptive Advisors ... & 11 others	57/100
6th	Sinopharm 2009, Beijing (China), Acquired	Developer of vaccines for infectious diseases	-	6 Dimensions Capital, Alpview Capital & 1 others	56/100
7th	Bavarian Nordic 1994, Hellerup (Denmark), Public	Developer of therapeutic vaccines against cancer and infectious diseases	-	Eiffel Investment Group, NB Capital & 1 others	56/100
8th	MAXVAX Biotechnology 2016, Lanzhou (China), Series D	Developer of vaccines for infectious diseases	$84.8M	Hillhouse, Korea Investment Partners & 10 others	54/100
9th	Hervolution 2011, Copenhagen (Denmark), Series A	Developer of immunotherapies for cancer treatment	$18.2M	EIC Fund, Serum Institute of India & 2 others	52/100
10th	Cellid 2014, Seoul (South Korea), Public	Developer of personalized vaccines to treat cancer and infectious diseases	-	DAOL Investment, DSC Investment & 9 others	50/100